| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H32O2 |
| Molecular Weight | 316.4776 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@@]1(O)CC[C@@H]2[C@H]3CCC4=CC(=O)CC[C@H]4[C@@H]3CC[C@@]12CC
InChI
InChIKey=FTBJKONNNSKOLX-XHCJJCCMSA-N
InChI=1S/C21H32O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h13,16-19,23H,3-12H2,1-2H3/t16-,17+,18+,19-,20-,21-/m1/s1
| Molecular Formula | C21H32O2 |
| Molecular Weight | 316.4776 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Norboletone (INN) (former proposed brand name Genabol), or norbolethone, is an anabolic steroid that was never marketed. It was first developed in 1966 by Wyeth Laboratories, and tested for use as an agent to encourage weight gain and for the treatment of short stature, but was never marketed commercially because of fears that it might be toxic. Norboletone is on the World Anti-Doping Agency's list of prohibited substances, and is therefore banned from use in most major sports.
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Patents
|
|
ENANTIOMER -> ENANTIOMER |
|
||
|
|
RACEMATE -> ENANTIOMER |
|
Showing 1 to 2 of 2 entries